Skip to content
Sign in

FBIO · NASDAQ

Fortress Biotech (FBIO) Stock Price & Fundamentals

$681.90−0.63%−$4.35End-of-day price as of Oct 9, 2026

Fortress Biotech (FBIO) closed at $681.90 on Oct 9, 2026, down 0.63% from the previous close of $686.25.

Share price, past year

1Y +10.09%

52-week range $606.59 – $722.18. Daily closing prices.
Monthly closing prices
Last closing price of each month
DateClose
Oct 9, 2026$681.90
Sep 30, 2026$710.79
Aug 31, 2026$690.45
Jul 31, 2026$721.09
Jun 30, 2026$701.50
May 29, 2026$689.08
Apr 30, 2026$679.09
Mar 31, 2026$681.94
Feb 27, 2026$614.91
Jan 30, 2026$609.32
Dec 31, 2025$663.29
Nov 28, 2025$622.46
Oct 31, 2025$662.26

Key statistics

Market cap
$22.71B
P/E (TTM)
252.6
EPS (TTM)
$2.70
Revenue (TTM)
$68.47M
Net income (TTM)
$111.82M
Shares outstanding
33.3M
Dividend yield
—
52-week range
$606.59 – $722.18

Fortress Biotech's market cap is $22.71B, based on a share price of $681.90 and 33.3M shares outstanding as of Jun 30, 2026.

Financials

Fortress Biotech reported revenue of $63.26M for fiscal 2025, up 9.69% from fiscal 2024.

Fortress Biotech earned net income of $6.82M in fiscal 2025, a net margin of 10.8%.

Annual revenue

FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Annual revenue by fiscal year; the table below lists the values.
Fortress Biotech annual financials by fiscal year, from SEC filings
Fiscal yearRevenueGrowthNet incomeNet marginEPS (diluted)Free cash flow
FY2025ended Dec 31, 2025$63.26M+9.7%$6.82M10.8%−$0.07—
FY2024ended Dec 31, 2024$57.68M−31.8%−$46.00M−79.8%−$2.69−$80.19M
FY2023ended Dec 31, 2023$84.51M+11.6%−$60.64M−71.8%−$8.47−$128.29M
FY2022ended Dec 31, 2022$75.74M+10.1%−$86.58M−114.3%−$239.43−$182.12M
FY2021ended Dec 31, 2021$68.79M+50.9%−$64.70M−94.1%−$11.84−$121.11M
FY2020ended Dec 31, 2020$45.60M+24.5%−$46.53M−102.0%−$9.75−$85.61M
FY2019ended Dec 31, 2019$36.63M+36.3%−$39.96M−109.1%−$10.94−$97.31M
FY2018ended Dec 31, 2018$26.88M+55.9%−$84.15M−313.0%−$29.09−$105.93M
FY2017ended Dec 31, 2017$17.25M+4.6%−$66.88M−387.8%−$24.14−$81.95M
FY2016ended Dec 31, 2016$16.48M—−$55.10M−334.3%−$20.69−$52.18M
Fortress Biotech quarterly results
QuarterRevenueNet incomeEPS (diluted)
Q2 FY2026ended Jun 30, 2026$18.72M−$468.00K−$0.08
Q1 FY2026ended Mar 31, 2026$16.04M$110.37M$2.82
Q4 FY2025ended Dec 31, 2025$16.08M−$3.94M−$0.15
Q3 FY2025ended Sep 30, 2025$17.63M$5.85M$0.11
Q2 FY2025ended Jun 30, 2025$16.41M$15.49M$0.45
Q1 FY2025ended Mar 31, 2025$13.14M−$10.58M−$0.48
Q4 FY2024ended Dec 31, 2024$15.12M−$6.77M−$0.16
Q3 FY2024ended Sep 30, 2024$14.63M−$12.87M−$0.76

Company profile

Name
Fortress Biotech, Inc.
Ticker
FBIO
Exchange
NASDAQ
Industry (SEC SIC)
Pharmaceutical Preparations
Headquarters
1111 Kane Concourse, Suite 301, Bay Harbor Islands, FL 33154
Incorporated in
DE
Fiscal year ends
December
SEC CIK
0001429260

Recent SEC filings

Frequently asked questions

What is Fortress Biotech's stock price?

Fortress Biotech (FBIO) closed at $681.90 on Oct 9, 2026, down 0.63% from the previous close of $686.25.

What is Fortress Biotech's market cap?

Fortress Biotech's market cap is $22.71B, based on a share price of $681.90 and 33.3M shares outstanding as of Jun 30, 2026.

How much revenue does Fortress Biotech make?

Fortress Biotech reported revenue of $63.26M for fiscal 2025, up 9.69% from fiscal 2024.

What is FBIO's P/E ratio?

Fortress Biotech's price-to-earnings ratio is 252.6, based on trailing twelve-month diluted EPS of $2.70.

Does Fortress Biotech pay a dividend?

Fortress Biotech's recent filings report no dividends declared over the last four quarters.

Sources and methodology

Fundamentals come from Fortress Biotech, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures